Australia's TGA Issues Safety Advisory on Unapproved Peptides Including BPC-157 and Retatrutide
Australia's Therapeutic Goods Administration warned of rising imports of unapproved peptide products promoted on social media, citing risks including severe allergic reactions, systemic inflammatory response, infection, and organ damage. Named products include BPC-157, GHK-Cu, TB-500, retatrutide, and CJC-1295 — often supplied as injectables.